These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 25845297)

  • 21. Management of nephropathy in patients with type 2 diabetes.
    Critchley JA; Zhao HL; Tomlinson B; Leung W; Thomas GN; Chan JC; Cockram CS
    Chin Med J (Engl); 2002 Jan; 115(1):129-35. PubMed ID: 11930647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Can progression to terminal renal insufficiency be avoided in diabetic nephropathy?].
    Luño J; Valderrábano F
    An Med Interna; 1998 Nov; 15(11):567-71. PubMed ID: 9882851
    [No Abstract]   [Full Text] [Related]  

  • 23. Diabetic nephropathy and multiorgan protection. Part II.
    Gluhovschi G; Gluhovschi C; Vlad A; Timar R; Bob F; Velciov S; Bozdog G; Petrica L
    Rom J Intern Med; 2011; 49(4):237-49. PubMed ID: 22568268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study.
    Remuzzi G; Macia M; Ruggenenti P
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S90-7. PubMed ID: 16565256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-analysis of the relationship between ACE I/D gene polymorphism and end-stage renal disease in patients with diabetic nephropathy.
    Yu ZY; Chen LS; Zhang LC; Zhou TB
    Nephrology (Carlton); 2012 Jul; 17(5):480-7. PubMed ID: 22385293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockers.
    Ivory SE; Packham DK; Reutens AT; Wolfe R; Rohde RD; Lewis J; Atkins RC;
    Nephrology (Carlton); 2013 Jul; 18(7):516-24. PubMed ID: 23506627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetics of diabetic nephropathy.
    Merta M; Reiterova J; Rysavá R; Kmentová D; Tesar V
    Nephrol Dial Transplant; 2003 Jul; 18 Suppl 5():v24-5. PubMed ID: 12817062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
    Bakris GL; Toto RD; McCullough PA
    J Hum Hypertens; 2005 Feb; 19(2):139-44. PubMed ID: 15457206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan): Rationale and study design.
    Shikata K; Haneda M; Koya D; Suzuki Y; Tomino Y; Yamada K; Maeda S; Kawakami N; Uzu T; Nishimura M; Sato C; Ogawa D; Makino H;
    Diabetes Res Clin Pract; 2010 Feb; 87(2):228-32. PubMed ID: 19889469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and Management of Diabetic Nephropathy in Western Countries.
    Satirapoj B; Adler SG
    Kidney Dis (Basel); 2015 May; 1(1):61-70. PubMed ID: 27536666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus].
    Ravera M; Deferrari L; Ratto E; Vettoretti S; Parodi D; Deferrari G
    Ital Heart J Suppl; 2003 Mar; 4(3):210-6. PubMed ID: 12784755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The angiotensin II inhibition escape phenomenon in patients with type 2 diabetes and diabetic nephropathy].
    Shamkhlova MSh; Trubitsyna NP; Katsaia GV; Goncharov NP; Malysheva NM; Il'in AV; Nikankina LV; Koshel' LV; Shestakova MV
    Ter Arkh; 2008; 80(1):49-52. PubMed ID: 18326228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvements in the Management of Diabetic Nephropathy.
    Dounousi E; Duni A; Leivaditis K; Vaios V; Eleftheriadis T; Liakopoulos V
    Rev Diabet Stud; 2015; 12(1-2):119-33. PubMed ID: 26676665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benefits and cost of antihypertensive treatment in incipient and overt diabetic nephropathy.
    Parving HH
    J Hypertens Suppl; 1998 Jan; 16(1):S99-101. PubMed ID: 9534107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kidney involvement and disease in patients with diabetes.
    Chiarelli F; Trotta D; Verrotti A; Mohn A
    Panminerva Med; 2003 Mar; 45(1):23-41. PubMed ID: 12682618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel effective drugs for diabetic kidney disease? or not?
    Gentile G; Mastroluca D; Ruggenenti P; Remuzzi G
    Expert Opin Emerg Drugs; 2014 Dec; 19(4):571-601. PubMed ID: 25376947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cigarette smoking predicts faster progression of type 2 established diabetic nephropathy despite ACE inhibition.
    Chuahirun T; Wesson DE
    Am J Kidney Dis; 2002 Feb; 39(2):376-82. PubMed ID: 11840380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
    Packham DK; Alves TP; Dwyer JP; Atkins R; de Zeeuw D; Cooper M; Shahinfar S; Lewis JB; Lambers Heerspink HJ
    Am J Kidney Dis; 2012 Jan; 59(1):75-83. PubMed ID: 22051245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment.
    Samsu N
    Biomed Res Int; 2021; 2021():1497449. PubMed ID: 34307650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.